GET DAILY SIGNALSQT Imaging Holdings (QTI) Q3 2026 Earnings Preview: Tracking the Revenue Ramp
Key Takeaways
- QT Imaging Holdings (QTI) is scheduled to report its third quarter 2026 results on November 10, 2026, after the market close, with a conference call at 4:30 p.m. Eastern Time.
- Wall Street consensus projects revenue of roughly $10.79 million, more than doubling the $4.19 million reported in the year-ago quarter, alongside a net loss of about $0.09 per share.
- Investors will focus on scanner shipment volume and gross margin, which narrowed to 41% in the second quarter of 2026, down from 50% a year earlier.
- Recent catalysts, including Medicare outpatient reimbursement for QTscan effective January 2027 and a first Gulf Cooperation Council commercial order, set the stage for the quarter's narrative.
- The company reaffirmed full-year 2026 revenue guidance of approximately $39 million, a level that hinges on fulfilling distribution minimum order quantities.
Placing the Earnings in Context
QT Imaging Holdings (QTI), a medical device company commercializing its Breast Acoustic CT Scanner, is in the early stages of a rapid revenue ramp. Full-year 2025 revenue rose roughly 288% to $18.9 million, and management has guided to approximately $39 million for 2026. This quarter's report is a key test of whether that trajectory is sustainable as the company balances top-line growth against rising costs and narrowing gross margins. For investors, the results will clarify how effectively newly secured reimbursement, regulatory, and distribution milestones are translating into commercial momentum, and whether the company can narrow its losses while continuing to scale scanner placements. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Earnings Expectations
Analysts expect QT Imaging Holdings (QTI) to report revenue of approximately $10.79 million for the third quarter of 2026, which would represent growth of more than 150% compared with $4.19 million in the same period a year earlier. Consensus estimates call for a net loss of roughly $0.09 per share, a notable improvement from the $0.47 per-share loss recorded in the third quarter of 2025.
The company enters the report having just affirmed full-year 2026 revenue guidance of approximately $39 million. Key metrics investors will monitor include the number of Breast Acoustic CT scanners shipped, gross margin (which declined to 41% in the second quarter of 2026 from 50% a year earlier), operating expenses, and cash burn. Recent quarters show a mixed track record against estimates: second quarter 2026 revenue of $7.44 million missed the $7.60 million consensus, while first quarter 2026 revenue of $6.53 million modestly exceeded the $6.45 million estimate. Historically, the stock has reacted sharply to results, falling roughly 16.7% after first quarter 2026 earnings and about 5.3% after the second quarter report.
Market Reaction and Investor Sentiment
Sentiment heading into the third quarter 2026 report remains cautious. QTI shares have declined significantly over the past year, trading near the lower end of their 52-week range, and prior earnings events have triggered sharp intraday moves. The market's focus is split between the company's impressive revenue growth and its persistent losses, with margin compression and higher operating expenses weighing on the investment thesis. Key risk factors include execution on large distribution minimum order quantities, the pace of scanner adoption, and geopolitical disruptions that have previously affected commercial activity in parts of the Gulf region. Any shortfall in revenue or an unexpected widening of losses could amplify volatility given the stock's thin trading volume.
Forward Outlook and Key Factors to Monitor
Beyond the headline numbers, investors will be listening for management's progress on several fronts that could shape the next several quarters. First is the fulfillment of distribution minimum order quantities, which underpin the company's roughly $39 million revenue target for 2026 and represent a substantial contracted backlog through 2028.
Second, reimbursement and regulatory milestones remain pivotal. The Medicare outpatient reimbursement classification for QTscan, effective January 2027, and the newly effective CPT Category III code could support broader hospital adoption, while regulatory approvals in markets such as Saudi Arabia and the United Arab Emirates may unlock international distribution.
Finally, investors should watch cost trends and liquidity. Gross margin recovery, control of operating expenses, and cash burn will be closely scrutinized, as the company works to narrow losses and move toward a more sustainable financial profile. How management addresses the geopolitical factors affecting Gulf-region shipments will also be an important signal for the durability of near-term revenue growth. From what I see, one thing that stands out is how these elements could influence the path ahead.
Exploring AI Tools in My Research Process
In my own analysis of earnings situations like this one, I often turn to Tickeron’s AI Screener to quickly filter for comparable companies and spot patterns in volatility or momentum that might not be obvious from the numbers alone. It helps me cross-check industry trends and refine the questions I bring to the conference call without replacing my own judgment on the fundamentals.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
QTI in upward trend: price expected to rise as it breaks its lower Bollinger Band on November 05, 2026
QTI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 20 of 22 cases where QTI's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where QTI's RSI Indicator exited the oversold zone, 17 of 19 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 39 of 66 cases where QTI's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 59%.
The Moving Average Convergence Divergence (MACD) for QTI just turned positive on November 09, 2026. Looking at past instances where QTI's MACD turned positive, the stock continued to rise in 28 of 57 cases over the following month. The odds of a continued upward trend are 49%.
Following a +1.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where QTI advanced for three days, in 122 of 168 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on QTI as a result. In 51 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 57%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where QTI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for QTI entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.229) is normal, around the industry mean (4.142). P/E Ratio (-1.460) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (1.267) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. QTI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QTI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement